The chemotherapy drugs 5-FU and capecitabine could harm or kill you if you have a variant in the DPYD gene. Request genetic testing before you take these drugs.
of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange ...
Genetic technology in medicine has evolved to the point where it is now being used to improve care and outcomes for ...
Genetic testing could lower the risk of adverse drug reactions for thousands of patients with cancer
A new study led by Genomics England and Queen Mary University of London estimates that genetic testing could identify ...
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...
This collaboration will enable Evexia Diagnostics'clinicians to access Genomind's advanced pharmacogenetic testing, empowering them to make more informed decisions and provide personalized care ...
Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.
10d
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...
MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback